Form 8-K - Current report:
SEC Accession No. 0001493152-22-014290
Filing Date
2022-05-18
Accepted
2022-05-18 12:29:23
Documents
14
Period of Report
2022-05-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 50894
2 ex4-1.htm EX-4.1 91403
3 ex10-1.htm EX-10.1 82009
  Complete submission text file 0001493152-22-014290.txt   438106

Data Files

Seq Description Document Type Size
4 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ppcb-20220512.xsd EX-101.SCH 2956
5 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ppcb-20220512_lab.xml EX-101.LAB 34240
6 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ppcb-20220512_pre.xml EX-101.PRE 22357
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3373
Mailing Address 302/6 BUTLER STREET CAMBERWELL, VICTORIA C3 3124
Business Address 302/6 BUTLER STREET CAMBERWELL, VICTORIA C3 3124 61-03-9882-0780
Propanc Biopharma, Inc. (Filer) CIK: 0001517681 (see all company filings)

EIN.: 300662986 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 000-54878 | Film No.: 22937830
SIC: 2834 Pharmaceutical Preparations